Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy,Movement Disorders

当前位置： X-MOL 学术 › Mov. Disord. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy
Movement Disorders ( IF 8.6 ) Pub Date : 2021-09-17 , DOI: 10.1002/mds.28785
Dario Arnaldi _{1,

2} , Pietro Mattioli ₁ , Francesco Famà _{1,

2} , Nicola Girtler _{1,

2} , Andrea Brugnolo _{1,

2} , Matteo Pardini _{1,

2} , Andrea Donniaquio ₁ , Federico Massa ₁ , Beatrice Orso ₁ , Stefano Raffa ₃ , Matteo Bauckneht _{2,

3} , Silvia Morbelli _{2,

3} , Flavio Nobili _{1,

2}

Affiliation

Dopamine transporter single photon-emission computed tomography (DAT-SPECT) is the strongest risk factor for phenoconversion in patients with idiopathic rapid eye movement (REM)-sleep behavior disorder (iRBD). However, it might be used as a second-line stratification tool in clinical trials, because it is expensive and mini-invasive.

中文翻译：